Angiotech Pharmaceuticals
Angiotech is a pharmaceutical company in Vancouver, British Columbia, Canada. Its products enhance the performance of medical devices and biomaterials through the use of pharmacotherapeutics. Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury.
In April 2010, Angiotech acquired Haemacure manufacturing to develop human biological adhesives, hemostats and therapeutic proteins.
Angiotech, based in Vancouver, British Columbia, was founded in 1992 by William L. Hunter, M.D., Lindsay Machan, M.D., and Larry Arsenault, Ph.D.
In 2017, Angiotech was acquired by a consortium led by the U.S. healthcare investment firm Vivo Capital and China's ZQ Capital.
